| 摘要 |
The present invention provides a method for monitoring the response to treatment in a patient undergoing breast cancer therapy, comprising detecting the presence of a loss-of-function-related genetic alteration in the PAPPA gene or its regulatory or promoter sequences in a sample obtained from the patient wherein if the genetic alteration is present but its quantitative level decreases during treatment, this is indicative of response to therapy, whereas, if there is no change or upward change in its quantitative level during therapy, this is indicative of non-response to therapy. The invention also relates to the use of specific biological markers for monitoring for relapse, and aiding the screening, primary diagnosis and staging of breast cancer. |
